JP6996844B2 - 体細胞可動要素の分析のための方法、およびその使用 - Google Patents

体細胞可動要素の分析のための方法、およびその使用 Download PDF

Info

Publication number
JP6996844B2
JP6996844B2 JP2016572365A JP2016572365A JP6996844B2 JP 6996844 B2 JP6996844 B2 JP 6996844B2 JP 2016572365 A JP2016572365 A JP 2016572365A JP 2016572365 A JP2016572365 A JP 2016572365A JP 6996844 B2 JP6996844 B2 JP 6996844B2
Authority
JP
Japan
Prior art keywords
mei
nucleic acid
sequence
acid sample
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512491A (ja
JP2017512491A5 (cg-RX-API-DMAC7.html
Inventor
ブラウン，キース
Original Assignee
ジャンプコード ゲノミクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャンプコード ゲノミクス，インク． filed Critical ジャンプコード ゲノミクス，インク．
Publication of JP2017512491A publication Critical patent/JP2017512491A/ja
Publication of JP2017512491A5 publication Critical patent/JP2017512491A5/ja
Application granted granted Critical
Publication of JP6996844B2 publication Critical patent/JP6996844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016572365A 2014-02-27 2015-02-27 体細胞可動要素の分析のための方法、およびその使用 Active JP6996844B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461945791P 2014-02-27 2014-02-27
US61/945,791 2014-02-27
PCT/US2015/018115 WO2015131110A1 (en) 2014-02-27 2015-02-27 Methods for analysis of somatic mobile elements, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020091511A Division JP2020156491A (ja) 2014-02-27 2020-05-26 体細胞可動要素の分析のための方法、およびその使用

Publications (3)

Publication Number Publication Date
JP2017512491A JP2017512491A (ja) 2017-05-25
JP2017512491A5 JP2017512491A5 (cg-RX-API-DMAC7.html) 2018-04-12
JP6996844B2 true JP6996844B2 (ja) 2022-02-03

Family

ID=54009677

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016572365A Active JP6996844B2 (ja) 2014-02-27 2015-02-27 体細胞可動要素の分析のための方法、およびその使用
JP2020091511A Pending JP2020156491A (ja) 2014-02-27 2020-05-26 体細胞可動要素の分析のための方法、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020091511A Pending JP2020156491A (ja) 2014-02-27 2020-05-26 体細胞可動要素の分析のための方法、およびその使用

Country Status (10)

Country Link
US (2) US20160376663A1 (cg-RX-API-DMAC7.html)
EP (2) EP3943615A1 (cg-RX-API-DMAC7.html)
JP (2) JP6996844B2 (cg-RX-API-DMAC7.html)
CN (2) CN114250301A (cg-RX-API-DMAC7.html)
AU (2) AU2015222802B2 (cg-RX-API-DMAC7.html)
CA (3) CA2940669C (cg-RX-API-DMAC7.html)
DK (1) DK3110975T3 (cg-RX-API-DMAC7.html)
ES (1) ES2894048T3 (cg-RX-API-DMAC7.html)
PL (1) PL3110975T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015131110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
BR112015003354A8 (pt) 2012-08-14 2018-01-16 10X Genomics Inc métodos e composições de microcápsula
EP3567116A1 (en) 2012-12-14 2019-11-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2900481A1 (en) 2013-02-08 2014-08-14 10X Genomics, Inc. Polynucleotide barcode generation
EP3828285B1 (en) 2013-05-23 2023-12-13 The Board of Trustees of the Leland Stanford Junior University Transposition into native chromatin for personal epigenomics
US20180113137A1 (en) * 2013-10-18 2018-04-26 Tcm Biotech International Corp. Method for detecting the quantity of biomarker and identifying disease status
PL3102722T3 (pl) 2014-02-04 2021-03-08 Jumpcode Genomics, Inc. Frakcjonowanie genomu
KR102596508B1 (ko) 2014-04-10 2023-10-30 10엑스 제노믹스, 인크. 시약을 캡슐화 및 구획화하기 위한 유체 디바이스, 시스템, 및 방법, 및 이의 응용
KR20170026383A (ko) 2014-06-26 2017-03-08 10엑스 제노믹스, 인크. 핵산 서열의 분석
EP4574974A3 (en) 2014-06-26 2025-10-08 10x Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
US20160122817A1 (en) 2014-10-29 2016-05-05 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
SG11201705615UA (en) 2015-01-12 2017-08-30 10X Genomics Inc Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
CN107532202A (zh) 2015-02-24 2018-01-02 10X 基因组学有限公司 用于靶向核酸序列覆盖的方法
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
WO2016138292A1 (en) 2015-02-25 2016-09-01 Igenomx International Genomics Corporation Methods and compositions for in silico long read sequencing
EP4144861B1 (en) 2015-12-04 2024-09-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11339427B2 (en) 2016-02-12 2022-05-24 Jumpcode Genomics, Inc. Method for target specific RNA transcription of DNA sequences
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
CN105886645A (zh) * 2016-05-27 2016-08-24 福建爱我健康生物科技有限公司 一种用于评估皮肤抗皱情况的引物和探针及试剂盒
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
EP4310183B1 (en) 2017-01-30 2025-07-09 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US20180340169A1 (en) 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
CN109526228B (zh) 2017-05-26 2022-11-25 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
CN107245529A (zh) * 2017-08-08 2017-10-13 杭州千麦医学检验所有限公司 血液病融合基因筛查方法
WO2019099751A1 (en) 2017-11-15 2019-05-23 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
DK3746564T3 (da) 2018-01-29 2023-01-30 St Jude Childrens Res Hospital Inc Fremgangsmåde til nukleinsyreamplifikation
EP4299755A3 (en) 2018-02-05 2024-04-10 The Board of Trustees of the Leland Stanford Junior University Systems and methods for multiplexed measurements in single and ensemble cells
CN108384846B (zh) * 2018-02-28 2020-06-16 固安博健生物技术有限公司 C11orf95基因及其表达产物在诊治类风湿性关节炎和骨关节炎方面的应用
SG11202009889VA (en) 2018-04-06 2020-11-27 10X Genomics Inc Systems and methods for quality control in single cell processing
CN112941155B (zh) * 2018-05-14 2023-07-14 北京艾克伦医疗科技有限公司 具有茎环结构的dna引物对及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102102107B1 (ko) * 2019-05-30 2020-04-20 단국대학교 천안캠퍼스 산학협력단 이동성 유전인자 SINE 선택적 발굴을 위한 HiSeq 시퀀서 기반의 DNA 라이브러리 제작 방법
CA3146298A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
EP4021581A4 (en) * 2019-08-30 2023-08-30 Foundation Medicine, Inc. KMT2A-MAML2 FUSION MOLECULES AND USES THEREOF
CN118891374A (zh) * 2022-03-24 2024-11-01 南京传奇生物科技有限公司 制备dna文库和检测逆转录病毒整合位点的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508082A (ja) 1999-09-07 2003-03-04 デコード ジェネティクス イーエッチエフ． ヒト可動性因子を使用する長領域ｐｃｒによる遺伝子における変更の検出

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9596098A (en) * 1997-09-29 1999-04-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Display technique for identifying line-1 insertion site polymorphisms
HUP0201423A3 (en) * 1999-04-01 2004-12-28 Dna Landmarks Inc St Jean Rich A novel type of transposon-based genetic marker
AU2003209453A1 (en) * 2002-03-05 2003-09-16 Arrow Therapeutics Limited Transposon
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
US8071310B2 (en) * 2005-11-14 2011-12-06 Keygene Nv Method for the high throughput screening of transposon tagging populations and massive parallel sequence identification of insertion sites
AU2008245546A1 (en) * 2007-04-25 2008-11-06 John Wayne Cancer Institute Use of methylated or unmethylated LINE-I DNA as a cancer marker
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
EP2789694A1 (en) * 2009-04-02 2014-10-15 Fluidigm Corporation Microfluidic device with reaction product recovery system
US9028561B2 (en) * 2009-05-05 2015-05-12 Milliken & Company Bluing composition and method for treating textile articles using the same
WO2011017404A2 (en) * 2009-08-05 2011-02-10 The Salk Institute For Biological Studies Retroelements and mental disorders and methods of measuring l1 retrotransposition
CN103517990A (zh) * 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508082A (ja) 1999-09-07 2003-03-04 デコード ジェネティクス イーエッチエフ． ヒト可動性因子を使用する長領域ｐｃｒによる遺伝子における変更の検出

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell, 2010, Vol. 141, pp. 1253-1261
Cell, 2013, Vol. 153, pp. 101-111

Also Published As

Publication number Publication date
US20160376663A1 (en) 2016-12-29
EP3110975A4 (en) 2017-12-06
AU2021240134A1 (en) 2021-10-28
US20230193401A1 (en) 2023-06-22
WO2015131110A1 (en) 2015-09-03
AU2015222802A1 (en) 2016-10-13
CA3214905A1 (en) 2015-09-03
CN106414770A (zh) 2017-02-15
AU2021240134B2 (en) 2024-08-29
DK3110975T3 (da) 2021-10-11
CA3212153A1 (en) 2025-07-07
EP3110975B1 (en) 2021-07-07
JP2017512491A (ja) 2017-05-25
EP3110975A1 (en) 2017-01-04
EP3943615A1 (en) 2022-01-26
CN114250301A (zh) 2022-03-29
AU2015222802B2 (en) 2021-07-01
JP2020156491A (ja) 2020-10-01
PL3110975T3 (pl) 2021-12-13
CA2940669C (en) 2023-10-03
CA2940669A1 (en) 2015-09-03
ES2894048T3 (es) 2022-02-11

Similar Documents

Publication Publication Date Title
JP6996844B2 (ja) 体細胞可動要素の分析のための方法、およびその使用
US20240327926A1 (en) Multigene analysis of tumor samples
AU2017225876B2 (en) Methods and systems for evaluating tumor mutational burden
AU2019286402B8 (en) Compositions and methods for evaluating genomic alterations
AU2016258171B2 (en) Liposomal preparations for non-invasive-prenatal or cancer screening
US20220389517A1 (en) Method for determining presence or absence of risk of developing cancer
HK40070305A (en) Methods for analysis of somatic mobile elements, and uses thereof
US20250223641A1 (en) Target enrichment and quantification utilizing isothermally linear-amplified probes
Borecká Role of genetic factors responsible for development of pancreatic cancer
Suter Enhancer function driving cellular senescence, DNA damage repair, differentiation, and nuclear organization
Beauchamp Investigating the Role of ZBTB33 Loss in Clonal Hematopoiesis and Hematologic Malignancies
Qu Aberrant DNA methylation in acute myeloid leukemia
Alvarez Epigenetic regulation of DNA repair mediated by the histone methyltransferase DOT1L
Zhang The integrated genomic analyses of human cancers
Reid-Bayliss Highly accurate RNA and DNA sequencing: Application to longstanding questions in aging and cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200526

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200608

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200707

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211216

R150 Certificate of patent or registration of utility model

Ref document number: 6996844

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250